1
|
Moreau-Bachelard C, Campion L, Toulmonde M, Le Cesne A, Brahmi M, Italiano A, Mir O, Piperno-Neumann S, Laurence V, Firmin N, Penel N, Duffaud F, Chevreau C, Bertucci F, Narciso B, Dubray-Longeras P, Delcambre C, Saada-Bouzid E, Boudou-Rouquette P, Soulie P, Perrin C, Blay JY, Bompas E. Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG). ESMO Open 2022; 7:100402. [PMID: 35202953 PMCID: PMC9058906 DOI: 10.1016/j.esmoop.2022.100402] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Revised: 01/14/2022] [Accepted: 01/18/2022] [Indexed: 01/13/2023] Open
Abstract
Background Synovial sarcoma (SS) occurs in both adult and pediatric patients. The primary aim of this study is to describe the outcomes, prognostic factors, and treatment of patients with metastatic SS within a nationwide cohort. Patients and methods All pediatric and adult patients with metastatic SS are registered in the French Sarcoma Group database. Data were collected from the national database https://conticabase.sarcomabcb.org/ up to March 2020. Descriptive and comparative analyses were conducted using SAS 9.4 and Stata Special Edition 16.1 software. Results Between January 1981 and December 2019, 417 patients with metastatic SS from 17 French sarcoma centers were included, including 64 (15.3%) under the age of 26 years. Median age was 42.5 years (range 9-87 years). The metastases were synchronous (cohort 1) or metachronous (cohort 2) in 18.9% (N = 79) and 81.1% (N = 338) patients, respectively. Median overall survival (OS) from the date of metastasis was 22.3 months (95% confidence interval 19.7-24.1 months). First-line chemotherapy without ifosfamide and/or doxorubicin was unfavorable for progression-free survival and OS (P < 0.001). Concerning cohort 1, young age, surgery of the primary tumor, and single metastatic site were independent favorable prognostic factors for OS. In cohort 2, surgery within an expert French Sarcoma Group center, absence of chemotherapy in the perioperative setting, the lungs as a single metastatic site, time to first metastasis >12 months, local therapy, and ifosfamide in the first metastatic line were independent favorable prognostic factors. Conclusions The outcome of patients with metastatic SS is influenced by local treatment, management in reference centers, and cytotoxic treatments given in the perioperative and metastatic setting. METASYN is the largest retrospective study on metastatic adult and pediatric SS. This study confirms that surgery remains the mainstay for improving OS in reference centers. METASYN emphasizes the importance of focal treatment of metastases for OS. This study offers real-life results in a metastatic setting and is a useful support for developing new strategies.
Collapse
Affiliation(s)
| | - L Campion
- ICO Centre René Gauducheau, Oncology, Nantes, France; CNRS, Inserm, CRCINA, Nantes, France
| | - M Toulmonde
- Institut Bergonié, Medical Oncology, Bordeaux, France
| | - A Le Cesne
- Department of Ambulatory Cancer Care & Sarcoma Group, Gustave Roussy, Villejuif, France
| | - M Brahmi
- Centre Leon Berard, Medical Oncology, Lyon, France
| | - A Italiano
- Institut Bergonié, Medical Oncology, Bordeaux, France
| | - O Mir
- Department of Ambulatory Cancer Care & Sarcoma Group, Gustave Roussy, Villejuif, France
| | | | - V Laurence
- Institut Curie, Medical Oncology, Paris, France
| | - N Firmin
- Department of Medical Oncology, ICM, INSERM U1194, IRCM, Université Montpellier, Montpellier, France
| | - N Penel
- Centre Oscar Lambret, Medical Oncology, Lille, France
| | - F Duffaud
- Hôpital De La Timone, Medical Oncology, Marseille, Aix Marseille Université, Marseille, France
| | - C Chevreau
- IUCT Oncopole, Oncology, Medical Toulouse, Toulouse, France
| | - F Bertucci
- Institut Paoli-Calmettes (IPC), Medical Oncology, Marseille, France
| | - B Narciso
- CHRU Bretonneau, Medical Oncology, Tours, France
| | | | - C Delcambre
- Centre François Baclesse, Medical Oncology, Caen, France
| | - E Saada-Bouzid
- Centre Antoine Lacassagne, Medical Oncology, Nice, France
| | | | - P Soulie
- ICO Centre Paul Pain, Medical Oncology, Angers, France
| | - C Perrin
- Centre Eugène Marquis, Medical Oncology, Rennes, France
| | - J Y Blay
- Centre Leon Berard, Medical Oncology, Lyon, France
| | - E Bompas
- ICO Centre René Gauducheau, Oncology, Nantes, France.
| |
Collapse
|
2
|
Martin E, Blanc-Lapierre A, Campion L, Guérin-Charbonnel C, Seegers V. Minimisation versus randomisation stratifiée par bloc : impact du choix de la méthode sur la comparabilité des groupes et la mesure de l’effet traitement. Rev Epidemiol Sante Publique 2021. [DOI: 10.1016/j.respe.2021.04.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
3
|
Haeldermans T, Campion L, Kuppens T, Vanreppelen K, Cuypers A, Schreurs S. A comparative techno-economic assessment of biochar production from different residue streams using conventional and microwave pyrolysis. Bioresour Technol 2020; 318:124083. [PMID: 32916464 DOI: 10.1016/j.biortech.2020.124083] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 08/31/2020] [Accepted: 09/01/2020] [Indexed: 06/11/2023]
Abstract
A comparative techno-economic assessment and Monte Carlo risk analysis is performed on large scale (3 tonne/h) biochar production plants for conventional (CPS) and microwave (MWP) pyrolysis using six different residue streams. Both plants are viable with minimum selling prices between € 436/tonne and € 863/tonne for CPS, and between € 564/tonne and € 979/tonne for MWP. The CPS is therefore more viable than MWP as it is a simpler and more established technology. However, a 20% biochar price increase due to higher biochar quality makes the MWP technology more viable. Nevertheless, the discounted payback period remains higher than this of CPS due to the increased CAPEX. Biochar price is the most important determinant of a biochar production plant's feasibility, motivating the need for economic and market research on biochar prices in function of biochar characteristics to reduce fluctuations in widely varying biochar prices.
Collapse
Affiliation(s)
- T Haeldermans
- Act&Sorb, BVBA, Houthalen-Helchteren, Belgium; Research Group Nuclear Technology, CMK, Hasselt University, Diepenbeek, Belgium.
| | - L Campion
- Research Group of Environmental Economics, CMK, Hasselt University, Diepenbeek, Belgium
| | - T Kuppens
- Research Group of Environmental Economics, CMK, Hasselt University, Diepenbeek, Belgium
| | | | - A Cuypers
- Research Group of Environmental Biology, CMK, Hasselt University, Diepenbeek, Belgium
| | - S Schreurs
- Research Group Nuclear Technology, CMK, Hasselt University, Diepenbeek, Belgium
| |
Collapse
|
4
|
Supiot S, Pasquier D, Buthaud X, Magne N, Becckendorf V, Crehange G, Pommier P, Loos G, Hasbini A, Latorzeff I, Silva M, Denis F, Campion L, Vaugier L, Blanc-Lapierre A. OC-0210: Salvage radiotherapy in oligorecurrent pelvic node relapses of prostate cancer : a phase 2 trial. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00234-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
5
|
Frenel JS, Cartron PF, Gourmelon C, Campion L, Aumont M, Augereau P, Ducray F, Loussouarn D, Lallier L, Robert M, Campone M. 370MO FOLAGLI: A phase I study of folinic acid combined with temozolomide and radiotherapy to modulate MGMT gene promoter methylation in newly diagnosed MGMT non-methytated glioblastoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.479] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
6
|
Chan SR, Bignan G, Pierson E, Mahady S, Ta H, Schepens W, Thuring JW, Lim HK, Otieno M, Wilde T, Singer M, Bogdan N, Patel S, Luistro L, Campion L, Smith M, Wiley D, Packman K, Allegrezza M, Morgan C, Sendecki J, Van Aller G, Krosky D, Connolly P, Edwards J, Staquet K, Emanuel SL. Abstract 5567A: JNJ-‘6196: A next generation STING agonist with potent preclinical activity by the IV route. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-5567a] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The Stimulator of Interferon Genes (STING) protein is a key mediator of innate immunity that plays a central role in the immune response to invading pathogens (bacterial, viral) and transformed cells. A next generation human STING agonist, JNJ-‘6196 was developed that cures mice of their tumors in preclinical models when administered by the IV route. JNJ-‘6196 was rationally selected to have a weaker binding affinity and fast off rate but functionally is a strong cytokine inducer and an efficient activator of human dendritic cells. JNJ-‘6196 exhibits a unique cytokine induction profile in human PBMCs compared to other cyclic dinucleotides (CDNs) that are not curative by the IV route in mice with higher levels of pro-inflammatory cytokines that mediate antitumor activity and lower levels of those that promote suppressive M2 macrophages. In preclinical models of cancer in mice, JNJ-‘6196 eliminates bilateral tumors when administered IV, and demonstrates activity over a wide therapeutic range. Cured mice are immune to further re-challenge due to the expansion and persistence of tumor specific CD8+ T-cells following JNJ-‘6196 administration. Moreover, JNJ-‘6196 increased the effectiveness of checkpoint inhibitors, turning a PD-1 resistant model into a responsive model. Although it is a very potent inducer of antitumor cytokines in mouse and cyno, it is tolerated at similar dose levels as other CDNs that are not systemically active. The functional properties that confer systemic activity were investigated by comparing gene signatures of JNJ-‘6196 to another CDN that was not curative when administered by the IV route. Differences in the intensity of cytokine gene induction were likely responsible for systemic activity rather than genes that were selectively induced by this IV-active compound. The pharmacologic mode of action of JNJ-‘6196 was investigated and found to be Cmax driven based on efficacy and cytokine readouts. JNJ-‘6196 creates an immune inflamed microenvironment in tumors and could expand the population of patients that respond to immunotherapy. The ability to administer JNJ-'6196 systemically and the potential to synergize with other immunotherapeutics could create unique combination modalities and differentiate this compound from other STING agonists.
Citation Format: Szeman Ruby Chan, Gilles Bignan, Emily Pierson, Sally Mahady, Hayley Ta, Wim Schepens, Jan Willem Thuring, Heng Keang Lim, Monicah Otieno, Thomas Wilde, Monica Singer, Nancy Bogdan, Shefali Patel, Leo Luistro, Liam Campion, Melissa Smith, Diana Wiley, Kathryn Packman, Michael Allegrezza, Caitlin Morgan, Jocelyn Sendecki, Glenn Van Aller, Daniel Krosky, Peter Connolly, James Edwards, Kim Staquet, Stuart L. Emanuel. JNJ-‘6196: A next generation STING agonist with potent preclinical activity by the IV route [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5567A.
Collapse
Affiliation(s)
| | | | | | | | - Hayley Ta
- 1Janssen Pharmaceutical, Spring House, PA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Smith M, Chin D, Chan S, Mahady S, Campion L, Morgan C, Patel S, Chu G, Hughes A, Bignan G, Connolly P, Emanuel S, Packman K, Luistro LL. Abstract 5567: In vivo administration of the STING agonist, JNJ-67544412, leads to complete regression of established murine subcutaneous tumors. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-5567] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
STING (Stimulator of Interferon Genes) is an important mediator of innate and adaptive immunity that responds to invading cytosolic bacterial and viral pathogens, and double stranded DNA from transformed cells. Activation of the cGAS-STING pathway leads to pleiotropic cytokine (IFN-α, IFN-β, TNF-α, IL-6) production, maturation and activation of macrophages, and MHC class II expressing dendritic cells (DCs) with generation of CD8+ T cells. JNJ-67544412 (JNJ-4412) is a cyclic dinucleotide (CDN) developed as a STING agonist. JNJ-4412 binds both mouse and human STING and is more potent binding all the major human STING alleles than most other STING CDN agonists. JNJ-4412 phosphorylate STING and IRF3 and induces high levels of IFNβ and other cytokines in M1 and M2 macrophages, dendritic cells, and monocytes.
In syngeneic mouse tumor studies, JNJ-4412 was dosed intratumorally (i.t.) on a q3d x 3 or qweekly schedule resulting in significant tumor regression, complete cures and long-lasting antitumor immunity. Body weight loss (<20%) was observed but was transient and recoverable and could be mitigated by utilizing a qweekly schedule with no loss of activity. Proinflammatory cytokines such as IFN-α, IFN-β, IP-10, TNF-α, IL-6 and MCP-1 were detected in tumor and plasma after dosing. Combination studies with anti-PD-1 resulted in enhanced dose-dependent efficacy in treated tumors. In bilateral tumor studies, JNJ-4412 inhibited growth of contralateral un-injected tumors. Pharmacodynamic (PD) and mechanism of action (MOA) studies revealed increased number of CD8+ T cells in the treated tumors; increased apoptosis (cleaved caspase 3); loss of vascularization; decreased tumor cell proliferation and pronounced hemorrhagic necrosis in tumors. Rechallenge of cured mice demonstrated long-lasting antitumor immunity.
Thus, in vivo administration of JNJ-4412 potently activates the STING pathway resulting in inflammatory cytokine induction, activation of dendritic cells, proliferation of CD8+ T cells, increased apoptosis and curative antitumor efficacy with immunologic memory.
Citation Format: Melissa Smith, Diana Chin, Szeman Chan, Sally Mahady, Liam Campion, Caitlin Morgan, Shefali Patel, Gerald Chu, Anna Hughes, Gilles Bignan, Pete Connolly, Stuart Emanuel, Kathryn Packman, Leopoldo L. Luistro. In vivo administration of the STING agonist, JNJ-67544412, leads to complete regression of established murine subcutaneous tumors [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5567.
Collapse
Affiliation(s)
- Melissa Smith
- Janssen Research & Development, LLC, Spring House, PA
| | - Diana Chin
- Janssen Research & Development, LLC, Spring House, PA
| | - Szeman Chan
- Janssen Research & Development, LLC, Spring House, PA
| | - Sally Mahady
- Janssen Research & Development, LLC, Spring House, PA
| | - Liam Campion
- Janssen Research & Development, LLC, Spring House, PA
| | | | - Shefali Patel
- Janssen Research & Development, LLC, Spring House, PA
| | - Gerald Chu
- Janssen Research & Development, LLC, Spring House, PA
| | - Anna Hughes
- Janssen Research & Development, LLC, Spring House, PA
| | - Gilles Bignan
- Janssen Research & Development, LLC, Spring House, PA
| | - Pete Connolly
- Janssen Research & Development, LLC, Spring House, PA
| | | | | | | |
Collapse
|
8
|
Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis A, Debeaupuis E, Campion L, Kraeber-Bodéré F. Résultats préliminaires d’une étude prospective tep/tdm 68ga-psma chez des patients atteints de récidive occulte d’un cancer de la prostate : performances diagnostiques et impact sur la prise en charge thérapeutique. Prog Urol 2018. [DOI: 10.1016/j.purol.2018.07.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, Rouzier R, Faure C, Paillocher N, Chauvet MP, Houvenaeghel G, Gutowski M, De Blay P, Verhaeghe JL, Barranger E, Lefebvre C, Ngo C, Ferron G, Palpacuer C, Campion L. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat 2018; 173:343-352. [PMID: 30343457 DOI: 10.1007/s10549-018-5004-7] [Citation(s) in RCA: 128] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Accepted: 10/09/2018] [Indexed: 01/08/2023]
Abstract
PURPOSE GANEA2 study was designed to assess accuracy and safety of sentinel lymph node (SLN) after neo-adjuvant chemotherapy (NAC) in breast cancer patients. METHODS Early breast cancer patients treated with NAC were included. Before NAC, patients with cytologically proven node involvement were allocated into the pN1 group, other patient were allocated into the cN0 group. After NAC, pN1 group patients underwent SLN and axillary lymph node dissection (ALND); cN0 group patients underwent SLN and ALND only in case of mapping failure or SLN involvement. The main endpoint was SLN false negative rate (FNR). Secondary endpoints were predictive factors for remaining positive ALND and survival of patients treated with SLN alone. RESULTS From 2010 to 2014, 957 patients were included. Among the 419 patients from the cN0 group treated with SLN alone, one axillary relapse occurred during the follow-up. Among pN1 group patients, with successful mapping, 103 had a negative SLN. The FNR was 11.9% (95% CI 7.3-17.9%). Multivariate analysis showed that residual breast tumor size after NAC ≥ 5 mm and lympho-vascular invasion remained independent predictors for involved ALND. For patients with initially involved node, with negative SLN after NAC, no lympho-vascular invasion and a remaining breast tumor size 5 mm, the risk of a positive ALND is 3.7% regardless the number of SLN removed. CONCLUSION In patients with no initial node involvement, negative SLN after NAC allows to safely avoid an ALND. Residual breast tumor and lympho-vascular invasion after NAC allow identifying patients with initially involved node with a low risk of ALND involvement.
Collapse
Affiliation(s)
- Jean-Marc Classe
- Department of Surgical Oncology, Institut de Cancerologie de l'ouest, Saint-Herblain, Loire Atlantique, France.
| | - Cecile Loaec
- Department of Surgical Oncology, Institut de Cancerologie de l'ouest, Saint-Herblain, Loire Atlantique, France
| | - P Gimbergues
- Department of Surgical Oncology, Centre Jean Perrin, Clermont-Ferrand, France
| | - S Alran
- Department of Surgical Oncology, Institut Curie, Paris, Saint-cloud, France
| | | | - P F Dupre
- Department of Gynecology, Centre Hospitalier Universitaire, Brest, France
| | - Roman Rouzier
- Department of Surgical Oncology, Institut Curie, Paris, Saint-cloud, France
| | - C Faure
- Department of Surgical Oncology, Centre Leon Berard, Lyon, France
| | - N Paillocher
- Department of Surgical Oncology, Institut de Cancerologie de l'ouest, Saint-Herblain, Loire Atlantique, France
| | - M P Chauvet
- Department of Surgical Oncology, Centre Oscar Lambret, Lille, France
| | - G Houvenaeghel
- Department of Surgical Oncology, Institut Paoli Calmette, Marseille, France
| | - M Gutowski
- Department of Surgical Oncology, Centre Val d'Aurelle, Montpellier, France
| | - P De Blay
- Department of Gynecology and Obstetrics, Centre Hospitalier General, La Roche sur Yon, France
| | - J L Verhaeghe
- Department of Surgical Oncology, Centre Alexis Vautrin, Nancy, France
| | - E Barranger
- Department of Surgical Oncology, Centre Lacassagne, Nice, France
| | - C Lefebvre
- Department of Gynecology and Obstetrics, Centre Hospitalier Universitaire, Angers, France
| | - C Ngo
- Department of Gynecology, Centre Hospitalier Europeen Georges Pompidou, Paris, France
| | - G Ferron
- Department of Surgical Oncology, Institut Universitaire du Cancer-Centre Claudius Regaud, Toulouse, France
| | - C Palpacuer
- Biometrics, Institut de Cancerologie de l'ouest, Saint-Herblain, France
| | - L Campion
- Biometrics, Institut de Cancerologie de l'ouest, Saint-Herblain, France
| |
Collapse
|
10
|
Courtinard C, Asselain B, Brain E, Piot I, Payen O, Campion L, Jaffré A, Girerd-Chambaz N, Pérol D, Mathoulin-Pelissier S, Diéras V, Perrocheau G, Robain M. Construction et évaluation d’un substitut de l’indice fonctionnel ECOG (PS), mesure de l’état de santé général du patient au diagnostic du cancer du sein métastatique. Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.03.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
11
|
Vaugier L, Palpacuer C, Rio E, Pacteau V, Mauboussin M, Campion L, Pein F, Supiot S. PV-0623: Toxicity and Quality of Life of Salvage Pelvic Irradiation of Prostatic Cancer Node Relapse. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30933-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
12
|
Bordes V, Simorre M, Campion L, Lejeune F, Loirat Y, Dravet F, Bouffaut AL. Abstract P4-13-02: Exclusive fat grafting breast reconstruction after mastectomy: Aesthetic results, satisfaction and quality of life evaluation on 38 patients. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-13-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Autologous fat grafting has become a frequent, simply reproducible and low-risk technique in breast reconstruction. The potential risk of fat tissue transfer to the breast for oncologic patients remains to be discussed, but one must clearly distinguish the situation where there is a breast parenchyma left and where the whole gland has been removed, like in our study. Although lipotransfer has become very popular, only a limited number of case series have been reported up to date. The presented study evaluates aesthetic results and quality of life after exclusive fat grafting breast reconstruction.
Patients and methods: A retrospective study was performed in two French centers with five surgeons between February 2011 and June 2015. We included patients with prior breast cancer, treated by mastectomy and with a finished breast reconstruction with exclusive fat grafting. We excluded patients with implant or flap. For each patient, the aesthetic evaluation was threefold, performed by the patient, the surgeon and an extra person, using the same questionnaire. For the analysis of the cosmetic results, the patients, surgeons and the other person were asked to grade the result on a 0 to 10 scale, ranging from "very bad" to "very good". They were questioned about the global esthetic result, symmetry between the two breasts and reconstructed breast texture. Satisfaction was evaluated using a Breast-Q adapted questionnaire, elaborated by psycho-oncologists and surgeons. Quality of life was evaluated using WHOQOL-BREF 26. Statistical analysis was performed using stata 13.1 SE.
Results: We sent a questionnaire to 48 patients and we obtained 38 responses. The mean age of the patients was 52 years, 31 patients (81,6%) lived in couple and 29 patients (76,3%) were employed. We performed 190 fat grafting procedures with an average of 4,2 per patient. The mean total quantity of fat injected was 904 ml per patient with a mean quantity per procedure of 219 ml. The mean time between two procedures was 4,3 months. The average grade obtained for the global esthetic result was 7,3 +/- 1,8 out of 10 for patients, 7,6 +/-2 for the extra person and 7,9 +/- 1,4 for surgeons. For symmetry between the two breasts, the result was 7,1 +/- 1,9 and for the texture, it was 6,8 +/- 2,6. To the question "did the final result meet your expectations?” 81,5% (31/38) of the patients and 79% (30/38) of the surgeons said yes. Among the 29 patients having a professional activity, 86% (25/29) of patients were able to work between each fat grafting session. The handicap evaluation in the professional life for these patients from 0 "no handicap "to 10 " important handicap” showed a score of 2,24 +/-2,7. As for global quality of life evaluation, to the question: "how would you grade your quality of life?" 92,3 % (35/38) of the patients answered "good" or "very good" (vs. 72,0 % in the general population - p = 0.004).
Conclusion: Autologous fat grafting can be offered as a good alternative for total reconstruction after mastectomy with good aesthetic results and no deleterious impact on quality of life.
Citation Format: Bordes V, Simorre M, Campion L, Lejeune F, Loirat Y, Dravet F, Bouffaut A-L. Exclusive fat grafting breast reconstruction after mastectomy: Aesthetic results, satisfaction and quality of life evaluation on 38 patients [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-13-02.
Collapse
Affiliation(s)
- V Bordes
- ICO René Gauducheau, Nantes, France; CH, Saint Nazaire, France; Clinique Breteche, Nantes, France
| | - M Simorre
- ICO René Gauducheau, Nantes, France; CH, Saint Nazaire, France; Clinique Breteche, Nantes, France
| | - L Campion
- ICO René Gauducheau, Nantes, France; CH, Saint Nazaire, France; Clinique Breteche, Nantes, France
| | - F Lejeune
- ICO René Gauducheau, Nantes, France; CH, Saint Nazaire, France; Clinique Breteche, Nantes, France
| | - Y Loirat
- ICO René Gauducheau, Nantes, France; CH, Saint Nazaire, France; Clinique Breteche, Nantes, France
| | - F Dravet
- ICO René Gauducheau, Nantes, France; CH, Saint Nazaire, France; Clinique Breteche, Nantes, France
| | - A-L Bouffaut
- ICO René Gauducheau, Nantes, France; CH, Saint Nazaire, France; Clinique Breteche, Nantes, France
| |
Collapse
|
13
|
Du Rusquec P, Palpacuer C, Campion L, Patsouris A, Augereau P, Gourmelon C, Robert M, Dumas L, Folliard C, Campone M, Frenel JS. Efficacy of palbociclib plus fulvestrant in advanced Hormone Receptor-positive (HR+) metastatic breast cancer (MBC) pretreated with everolimus: Real-life data from the french temporary authorization for use (TAU) at the Institut de Cancérologie de l’Ouest. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Pistilli B, Lardy-Cleaud A, Jacquet E, Delaloge S, Cottu P, Debled M, Vanlemmens L, Leheurteur M, Divanon F, Gonçalves A, Laurent C, Coudert B, Chamorey E, Campion L, Mouret-Reynier MA, Breton M, Petit T, Simon G, Cailliot C, Bachelot T. FICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/HER2- negative metastatic breast cancer patients (MBC) ≤45 years old. A large observational multicenter cohort survival analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Classe JM, Loaec C, Alran S, Paillocher N, Tunon-Lara C, Gimbergues P, Faure-Virelizier C, Chauvet MP, Lasry S, Dupre PF, Verhaeghe JL, De Blaye P, Gutowski M, Barranger E, Lecuru F, Lefevre Lacoeuille C, Loussert L, Lambaudie E, Ferron G, Campion L. Abstract S2-07: Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GANEA 2 trial): Follow-up of a prospective multi-institutional cohort. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-s2-07] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Half of the patient treated with neoadjuvant chemotherapy (NAC) for a large operable breast cancer has no axillary lymph node involvement at the time of surgery. Sentinel lymph node detection (SLND), after NAC, is aimed to select patient who should be safely spared of an axillary lymphadenectomy (ALND).GANEA 2 is a French prospective multi institutional trial, aimed to assess SLND after NAC.
Objective
To assess the risk of relapse for patients without previous axillary node involvement treated with NAC followed with a SLND without a systematic lymphadenectomy.
Patients and Method
Inclusion: FIGO stage T1-T3 infiltrating breast carcinoma, indication of NAC.
Exclusion: inflammatory cancer, local relapse, contra-indication to NAC, NAC interrupted due to progressive disease.
Design: indication to plan a NAC, axillary sonography with fine needle cytology before NAC to select patients without lymph node involvement, SLND after NAC. ALND was mandatory in case of SLN involvement (macro or micro-metastasis) or SLND failure. Follow-up was scheduled with a medical visit / 6 months with axillary assessment and a mammography each year. Follow-up results are updated every 6 months.
Pathological analysis were carried out according to standard methods and classified according to the last American Joint Committee staging system.
Studied parameters were SLND detection rate, pathological results on breast specimen and nodes, rate of relapse (axilla, breast, metastasis), and survival.
Results
From July 2010 to February 2014, 587 patients were enrolled, from 17 institutions, and experienced breast tumor surgery and a SLND after NAC.
Each patient experienced breast surgery. A breast tumour pathological complete response was found in 21.3% (125/587).
SLND rate was 97% (570/587), with a median number of 2 sentinel nodes (1-9).
Patients with a sentinel detection failure (n=17) experienced a systematic lymphadenectomy, without any involvement (n=13), a micro-metastasis (n=2) and a macro-metastasis (n=2).
A total of 140 patients had at least one sentinel node involved: macro-metastasis (n=86), micro-metastasis (n=54). A lymphadenectomy was performed in 128 cases: metastasis free (n=100), macro-metastasis (n=17), micro-metastasis (n=11).
A total of 430 patients had a SLN metastasis free (75% ;430/570). A not mandatory lymphadenectomy was performed (n=14): metastasis free (n=11), macro-metastasis (n=2) and micro-metastasis (n=1). 17 patients were lost to follow-up.
A total of 399 patients without sentinel node involvement were followed 2.3 years (from 0.5 to 5.6 yrs). At 3 years overall survival was 97.8% [94.9-99.1], disease free survival was 94.8% [91.0-97.1%]. Six patients died. Fifteen patients experienced a relapse: 8 metastasis, 4 homolateral breast, 2 controlateral breast, 1 homolateral axillary relapse.
Conclusion
This is the most important series of patients followed 2.3 years after SLND without axillary lymphadenectomy after NAC for an advanced breast cancer, showing acceptable results. The current series validate the safety of this conservative strategies avoiding systematic lymphadenectomy to patients without initially involved axillary node treated with NAC.
Citation Format: Classe J-M, Loaec C, Alran S, Paillocher N, Tunon-Lara C, Gimbergues P, Faure-Virelizier C, Chauvet M-P, Lasry S, Dupre P-F, Verhaeghe J-L, De Blaye P, Gutowski M, Barranger E, Lecuru F, Lefevre Lacoeuille C, Loussert L, Lambaudie E, Ferron G, Campion L. Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GANEA 2 trial): Follow-up of a prospective multi-institutional cohort [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr S2-07.
Collapse
Affiliation(s)
- J-M Classe
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - C Loaec
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - S Alran
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - N Paillocher
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - C Tunon-Lara
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - P Gimbergues
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - C Faure-Virelizier
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - M-P Chauvet
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - S Lasry
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - P-F Dupre
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - J-L Verhaeghe
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - P De Blaye
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - M Gutowski
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - E Barranger
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - F Lecuru
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - C Lefevre Lacoeuille
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - L Loussert
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - E Lambaudie
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - G Ferron
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| | - L Campion
- Institut Cancérologie de l'Ouest Centre Gauducheau, Saint Herblain, France; Institut Curie, Paris, France; Institut Cancérologie de l'Ouest Centre Papin, Angers, France; Institut Bergonié, Bordeaux, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Curie, Saint Cloud, France; Centre Hospitalier Universitaire Morvan, Brest, France; Institut de Cancerologie de Lorraine, Nancy, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Lacassagne, Nice, France; Centre Hospitalier Europeen Pompidou, Paris, France; Centre Hospitalier Universitaire, Angers, France; Centre Paul Stauss, Strasbourg, France; Institut Paoli Calmettes, Marseille, France; Institut Universitaire de Cancerologie Claudius Regaud, Toulous, France
| |
Collapse
|
16
|
Bordes V, Campion L, Jezequel P, Lefrancois A, Boiffard F, Brillaud-Meflah V, Dravet F, Jaffre I, Classe JM. Abstract P2-01-33: Non-sentinel lymph nodes involvement in early breast cancer patients: Performance of two predictive nomograms integrating the analysis of sentinel nodes by one step nucleic acid amplification in a cohort of 299 patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-01-33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Backgrounds: Sentinel lymph node (SLN) biopsy is a highly accurate predictor of axillary status and has become the surgical axillary standard in breast cancer patients. About 50–70 % of patients with involved SLN have no additional non sentinel node (NSN) involved, suggesting that it be possible to avoid ALND in selected patients. Many tools have been developed to help surgeons in NSLN evaluation but they all need pathological data from tumor and SLN and can't be used during surgery. Developed for intraoperative detection of SLN macro or micrometastasis involvement, the semi-automated molecular one step nucleic acid amplification (OSNA), as accurate as pathology, is available. Two simple nomograms have been developed to predict NSN involvement based on the number of CK19 mRNA copy determined by OSNA:
· Nomogram developed by Peg V (Eur J Surg Oncol 2013): based on total tumoral load (TTL). TTL is defined as the addition of CK19 mRNA copies of each positive SLN (copies/μL). A TTL≥1.2 × 10(5) copies/ml (specificity=85.3%, negative predictive value (NPV) = 80%) can predict NSN involvement.
· Nomogram developed by Di Filippo F (Journal of Experimental & Clinical Cancer Research 2015): based on the number of CK19 mRNA copies and ultrasound tumor size. These two variables are categorized using quartiles with a score for each and the addition of both corresponds to a probability of NSN involvement (sensitivity = 98.1%, NPV = 92.5 %).
Patients and Methods: this is a retrospective study of 299 patients. Each patient had SLN involvement (macro or micrometastasis) and underwent a complementary ALND. The main objective was to evaluate the performance of each nomogram using a discrimination ability model, assessed by ROC analysis. Predictive accuracy was measured by the area under ROC curves (AUC) reported with its 95 % confidence interval. The second objective was to compare the two nomograms using Hanley & McNeil method, to test the statistical significance of the difference between the AUC. Analysis was performed using stata 13.1 SE.
Results: The mean age was 59, 1 year. Most patients were treated for an infiltrating ductal carcinoma (80.3%, 240/299). The mean ultrasound tumor size was 13 mm and the mean pathological tumor size was 15 mm. The median number of examined SLN was 2 with a macro-metastasis in 67, 6%, 202/299). 70 patients had involved nodes in ALND (23%).
The discrimination of N Peg, quantified with AUC was 0.685 (p<0, 00001). The discrimination of N Di Filippo, quantified with AUC was 0.72 (p<0, 00001).
Hanley & McNeil method shows that Di Filippo nomogram is significantly superior to Peg nomogram (p=0,048).
Conclusion: The current study shows that these two nomograms are reliable and can be used to predict NSLN involvement. The combination of molecular data and ultrasound tumor size seems to be more efficient than molecular data alone. These results are similar to results of nomogram studies based on pathological analysis but only these nomograms integrating molecular data can be used during the surgery.
Citation Format: Bordes V, Campion L, Jezequel P, Lefrancois A, Boiffard F, Brillaud-Meflah V, Dravet F, Jaffre I, Classe J-M. Non-sentinel lymph nodes involvement in early breast cancer patients: Performance of two predictive nomograms integrating the analysis of sentinel nodes by one step nucleic acid amplification in a cohort of 299 patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-01-33.
Collapse
Affiliation(s)
- V Bordes
- ICO Rene Gauducheau, Nantes, France
| | | | | | | | | | | | - F Dravet
- ICO Rene Gauducheau, Nantes, France
| | - I Jaffre
- ICO Rene Gauducheau, Nantes, France
| | | |
Collapse
|
17
|
Bordes V, Campion L, Lejeune F, Loirat Y, Boiffard F, Brillaud-Meflah V, Dravet F, Bouffaut AL. Abstract P3-14-04: Exclusive fat grafting breast reconstruction after mastectomy: Feasibility and complications on 54 patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-14-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Backgrounds: Autologous fat grafting has become a frequent, simply reproducible and low-risk technique in breast reconstruction. The potential risk of fat tissue transfer to the breast in oncologic patients remains to be discussed, but one must clearly distinguish the situation where there is a breast parenchyma left and where the whole gland has been removed, like in our study. Although lipotransfer has become very popular, only a limited number of case series have been reported up to date. The presented study describes an optimized treatment and complications for breast reconstruction after total mastectomy by lipotransfer alone.
Patients and methods: A retrospective study was performed in two French centers with five surgeons between February 2011 and June 2015, including 54 patients. Inclusion criteria were patients with prior breast cancer, treated by mastectomy and with a finished breast reconstruction with exclusive fat grafting. Exclusion criteria were prior reconstruction with implant or flap. We used two technics for liposuction: manual aspiration with syringes (pouret kit®) or waterjet assisted liposuction (body-jet®). The BRAVA® could be combined with the reconstruction. Our study had 2 main objectives: evaluate the factors influencing the number of surgical procedures and study the complications and carcinologic evolution. Statistical analysis was performed using stata 13.1 SE.
Results: We included 54 patients, 49 delayed reconstructions including two bilateral reconstructions and 5 immediate reconstructions. The morphologic data showed: a normal BMI for 70,3 % (38/54) patients and a bra cup A or B for 72,2 % (39/54). 39 patients had radiotherapy during the cancer treatment and the mean time between radiotherapy and reconstruction was 19 months. For the patients without radiotherapy, the mean time between mastectomy and reconstruction was 22 months. 6 patients (11%) were smoker or diabetic. We used manual aspiration in 37 patients (68,5 %) and hydro dissection in 17 patients (31,5%). 10 patients received BRAVA system in complement. We performed 231 fat grafting procedures with an average of 4,2 per patient. The mean total quantity of fat injected was 904 ml per patient with a mean quantity per procedure of 219 ml. The mean time between two procedures was 4,3 months. Only the prior radiotherapy treatment increases the number of fat grafting procedures significantly (p=0,02) and the use of hydro dissection with bodyjet decreases the number of fat grafting procedures significantly (p=0,04). We observed one failure of procedure requiring an implant and three patients with metastatic disease without local recurrence with a mean follow of 5, 2 years. We also observed 3% of infectious complications (7/231) and 19 patients presented fat necrosis (34%). Of these 19 cases of fat necrosis, 6 (11 %) required a surgery.
Conclusion: Autologous fat grafting can be proposed as an alternative for total reconstruction after mastectomy with a low level of complications and no local recurrence in our study. Only anterior radiotherapy increases the number of procedures probably due to fibrosis and lack of cutaneous flexibility.
Citation Format: Bordes V, Campion L, Lejeune F, Loirat Y, Boiffard F, Brillaud-Meflah V, Dravet F, Bouffaut A-L. Exclusive fat grafting breast reconstruction after mastectomy: Feasibility and complications on 54 patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-14-04.
Collapse
Affiliation(s)
- V Bordes
- ICO Rene Gauducheau, Nantes, France; Clinique BRETECHE, Nantes, France
| | - L Campion
- ICO Rene Gauducheau, Nantes, France; Clinique BRETECHE, Nantes, France
| | - F Lejeune
- ICO Rene Gauducheau, Nantes, France; Clinique BRETECHE, Nantes, France
| | - Y Loirat
- ICO Rene Gauducheau, Nantes, France; Clinique BRETECHE, Nantes, France
| | - F Boiffard
- ICO Rene Gauducheau, Nantes, France; Clinique BRETECHE, Nantes, France
| | - V Brillaud-Meflah
- ICO Rene Gauducheau, Nantes, France; Clinique BRETECHE, Nantes, France
| | - F Dravet
- ICO Rene Gauducheau, Nantes, France; Clinique BRETECHE, Nantes, France
| | - A-L Bouffaut
- ICO Rene Gauducheau, Nantes, France; Clinique BRETECHE, Nantes, France
| |
Collapse
|
18
|
Doré M, Martin S, Delpon G, Clément K, Campion L, Thillays F. Stereotactic radiotherapy following surgery for brain metastasis: Predictive factors for local control and radionecrosis. Cancer Radiother 2016; 21:4-9. [PMID: 27955888 DOI: 10.1016/j.canrad.2016.06.010] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Revised: 06/27/2016] [Accepted: 06/30/2016] [Indexed: 11/24/2022]
Abstract
PURPOSE To evaluate local control and adverse effects after postoperative hypofractionated stereotactic radiosurgery in patients with brain metastasis. METHODS We reviewed patients who had hypofractionated stereotactic radiosurgery (7.7Gy×3 prescribed to the 70% isodose line, with 2mm planning target volume margin) following resection from March 2008 to January 2014. The primary endpoint was local failure defined as recurrence within the surgical cavity. Secondary endpoints were distant failure rates and the occurrence of radionecrosis. RESULTS Out of 95 patients, 39.2% had metastatic lesions from a non-small cell lung cancer primary tumour. The median Graded Prognostic Assessment score was 3 (48% of patients). One-year local control rates were 84%. Factors associated with improved local control were no cavity enhancement on pre-radiation MRI (P<0.00001), planning target volume less than 12cm3 (P=0.005), Graded Prognostic Assessment score 2 or above (P=0.009). One-year distant cerebral control rates were 56%. Thirty-three percent of patients received whole brain radiation therapy. Histologically proven radionecrosis of brain tissue occurred in 7.2% of cases. The size of the preoperative lesion and the volume of healthy brain tissue receiving 21Gy (V21) were both predictive of the incidence of radionecrosis (P=0.010 and 0.036, respectively). CONCLUSION Adjuvant hypofractionated stereotactic radiosurgery to the postoperative cavity in patients with brain metastases results in excellent local control in selected patients, helps delay the use of whole brain radiation, and is associated with a relatively low risk of radionecrosis.
Collapse
Affiliation(s)
- M Doré
- Service de radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, 2, boulevard Jacques-Monod, 44805 Saint-Herblain, France.
| | - S Martin
- Service de neurochirurgie, centre hospitalier universitaire Laënnec, boulevard Jacques-Monod, 44805 Saint-Herblain, France
| | - G Delpon
- Service de physique médical, institut de cancérologie de l'Ouest René-Gauducheau, 2, boulevard Jacques-Monod, 44805 Saint-Herblain, France
| | - K Clément
- Service de radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, 2, boulevard Jacques-Monod, 44805 Saint-Herblain, France
| | - L Campion
- Département de biostatistique, institut de cancérologie de l'Ouest René-Gauducheau, 2, boulevard Jacques-Monod, 44805 Saint-Herblain, France
| | - F Thillays
- Service de radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, 2, boulevard Jacques-Monod, 44805 Saint-Herblain, France
| |
Collapse
|
19
|
Hetet J, Colls P, Pocholle P, Chauveau P, Campion L. Cryothérapie prostatique de rattrapage pour récidive locale de cancer de prostate après radiothérapie externe : expérience initiale. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Jouglar E, Thomas L, de la Rochefordière A, Noël G, Le Blanc-Onfroy M, Delpon G, Campion L, Mahé MA. Toxicity and early clinical outcomes in cervical cancer following extended field helical tomotherapy to para-aortic lymph nodes. Cancer Radiother 2016; 20:794-800. [PMID: 28270323 DOI: 10.1016/j.canrad.2016.06.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2016] [Revised: 06/10/2016] [Accepted: 06/25/2016] [Indexed: 11/17/2022]
Abstract
PURPOSE To evaluate toxicity and early disease outcome among patients treated for cervical cancer with extended-field helical tomotherapy to the para-aortic nodes. PATIENTS AND METHODS Thirty-eight patients (International Federation of Gynecology and Obstetrics [FIGO] stage IB2-IVA) from four institutions received extended-field helical tomotherapy and were retrospectively evaluated. All had nodal disease. Para-aortic lymph nodes were involved in 31 patients. Patients were assessed for toxicity using version 4 of the National Cancer Institute's common terminology criteria for adverse events. Survival curves were plotted using Kaplan-Meier estimates. RESULTS All patients underwent radiation to the tumor region (median dose: 45Gy; range: 44-66Gy), pelvic lymph nodes and para-aortic lymph nodes (median dose: 45Gy; range: 44-60Gy). The median dose to positive lymph nodes was 55Gy (range: 45-65Gy). All received platinum-based chemotherapy (31 concurrently). The median follow-up was 15months. Acute toxicity events observed included one patient with grade 5 febrile neutropenia, 11 patients (29%) with grade 3 hematologic complications. Grades 3-4 gastrointestinal and genitourinary toxicities occurred in six (16%) and four (11%) patients, respectively. Three patients had grade 3 pelvic pain (8%). The 6- and 18-month overall survival rates were 94.7 and 63.9%, respectively. The 18-month locoregional control, disease-free survival, and late grade 3 toxicity rates were 60.2, 43.3 and 7.3%, respectively. CONCLUSION Extended-field helical tomotherapy was associated with low rates of acute gastrointestinal and genitourinary toxicities with early survival and locoregional control similar to other published series.
Collapse
Affiliation(s)
- E Jouglar
- Department of Radiation Oncology, institut de cancérologie de l'Ouest centre René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France.
| | - L Thomas
- Department of Radiation Oncology, institut Bergonié, 229, cours de l'Argonne, 33000 Bordeaux, France
| | - A de la Rochefordière
- Department of Radiation Oncology, institut Curie, 26, rue de l'Ulm, 75005 Paris, France
| | - G Noël
- Department of Radiation Oncology, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67000 Strasbourg, France
| | - M Le Blanc-Onfroy
- Department of Radiation Oncology, institut de cancérologie de l'Ouest centre René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France
| | - G Delpon
- Department of Medical Physics, institut de cancérologie de l'Ouest centre René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France
| | - L Campion
- Department of Statistics, Institut de cancérologie de l'Ouest centre René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France
| | - M-A Mahé
- Department of Radiation Oncology, institut de cancérologie de l'Ouest centre René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France
| |
Collapse
|
21
|
Dore M, Campion L, Delpon G, Thillays F, Martin S. Hypofractionated Stereotactic Radiation Therapy Following Surgical Resection for Brain Metastases: A Retrospective Analysis of 95 Patients. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
Blay C, Thillays F, Josset Gaudaire S, Campion L, Liberge R, Jasnot J, Mahé M. Série nantaise de 30 patients traités par radiothérapie en conditions stéréotaxiques au NovalisTM pour un cancer bronchopulmonaire non à petites cellules de stade 1. Cancer Radiother 2015. [DOI: 10.1016/j.canrad.2015.07.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Doré M, Martin S, Campion L, Delpon G, Thillays F. Irradiation hypofractionnée en conditions stéréotaxiques postopératoire des métastases cérébrales : analyse chez 95 patients. Cancer Radiother 2015. [DOI: 10.1016/j.canrad.2015.07.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
24
|
Patsouris A, Septans A, Paillard M, Pivot X, Soibinet P, Jovenin N, Robert M, Gourmelon C, Korembaum C, Petit T, Martin-babau J, Brunot A, Lefeuvre-plesse C, Adele M, Bourgeois H, Som M, Uwer L, Campone M, Campion L, Tredan O. 1865 Activity and toxicity profile of eribulin mesylate in heavily pretreated metastatic breast cancer: An observational study (EVHALAVEN). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30815-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Martin-babau J, Robert M, Septans A, Paillard M, Pivot X, Soibinet P, Gourmelon C, Brunot A, Lefeuvre-plesse C, Korenbaum C, Petit T, Marquis A, Bourgeois H, Uwer L, Som M, Desclos H, Campone M, Campion L, Tredan O, Patsouris A. 1320 Eribulin mesylate in metastatic breast cancer, a focus on safety and efficacy in elderly patients. Results from the EVHALAVEN multicentric retrospective cohort. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30563-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Oger AS, Boukerrou M, Cutuli B, Campion L, Rousseau E, Bussières E, Raro P, Classe JM. [Male breast cancer: prognostic factors, diagnosis and treatment: a multi-institutional survey of 95 cases]. ACTA ACUST UNITED AC 2015; 43:290-6. [PMID: 25818033 DOI: 10.1016/j.gyobfe.2015.02.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2014] [Accepted: 02/10/2015] [Indexed: 11/28/2022]
Abstract
OBJECTIVES The optimal treatment for male breast cancer is not known because male breast cancer is a rare disease. It represents as little as 0.6% of all breast cancers and less than 1% of human cancers. The aim was to analyze the clinical, histological and therapeutic characteristics of 95 men cared for breast cancer between 2000 and 2010 in four hospitals, and determine predictors of poor prognosis to improve care of male breast cancer. METHODS This study is a multi-institutional survey, retrospective, involving four French institutions: Cancer Institute of the West (ICO), Reunion Island South hospital group, the hospital group of Dax, and the Bergonié Institute. All carcinomas in situ or invasive breast occurred in male patients were included. An analysis of clinical, histological and therapeutic features was performed. Statistical analysis of our study focused on the overall survival of patients and specific method of Kaplan-Meier, enabling search for predictors of poor prognosis. RESULTS The mean age was 65 years. Thirty-seven percent of patients were overweight or obese. It was in 88% of cases of palpable tumor whose average size was 26.29mm. Ninety patients, none had a lesion palpable T0, 44% T1 tumors, 38% T2 tumors, 3% had a T3 tumors, and finally 10% T4 tumors. The histological type was the most common invasive ductal carcinoma (87%). He found a similar proportion of patients with or without lymph node involvement. N+ patients, capsular rupture was observed in 29% of cases. Receptor positivity was found, estrogen in 95% of cases and progesterone in 83% of cases. Additional irradiation was performed in 75% of patients and chemotherapy in 37% of patients. Overall survival was 79.2% at five years and 70.8% at ten years. Age, tumor size and histological capsular rupture are factors that significantly influence the overall survival and specific. CONCLUSION Male breast cancer is a different pathology of breast cancer in women. The majority of recommendations suggest treating men who are diagnosed with breast cancer, using the guidelines applied to postmenopausal women treatments. There is no study based on male population that has evaluated these treatment modalities in terms of impact on survival. The diagnosis is usually made at later stages, and tumor size is often greater. Histological characteristics also differ. However, the treatment is almost identical.
Collapse
Affiliation(s)
- A-S Oger
- ICO Paul-Papin, 2, rue Moll, 49933 Angers cedex 9, France.
| | - M Boukerrou
- CHU de la Réunion, groupe hospitalier Sud Réunion BP 350, 97448 Saint-Pierre cedex, Réunion
| | | | - L Campion
- ICO René-Gauducheau, 44805 Saint-Herblain cedex, France
| | - E Rousseau
- Centre hospitalier de Dax, 40107 Dax, France
| | | | - P Raro
- ICO Paul-Papin, 2, rue Moll, 49933 Angers cedex 9, France
| | - J-M Classe
- ICO René-Gauducheau, 44805 Saint-Herblain cedex, France
| |
Collapse
|
27
|
Metges JP, Lebot MA, Faroux R, Riaud F, Gamelin E, Capitain O, Guérin Meyer V, Leynia P, Douillard JY, Senellart H, Rochard S, Louvigné C, Campion L, Dupuis O, Grollier C, Achour NA, Person B, Raoul JL, Boucher E, Bertrand C, Ramée JF, Guivarch L, Etienne PL, Roussel S, Desclos H, Julien MN, Labarre MI, Klein V, Bessard R, Stampfli C, Royet F, Faycal J, Gouva S, Le Bihan G, Couturier M, Gourlaouen A, Bertholom C, Porneuf M, Jobard E, Peguet E, Grasset D, Bouret JF, Bicheler V, Ulvoas A, Miglianico L, Chouzenoux C, Deguiral P, Derenne L, Martin D, Langlet PM, Bodin C, Rossi V, Barré S, Cojocarasu O, Naveau Ploux C, Vidal AM, Cumin I, Egreteau J, Brouard A, Matysiak Budnik T, Thomaré P, Le Bris Michel AS, Piriou G, Largeau R, Elhannani C, Crespeau E, Suberville F, Bourgeois H, Riche C, Lagadec DD, Marhuenda F, Grudé F. Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas ( Observatoire dédié au Cancer Bretagne / Pays de la Loire). ONCOLOGIE 2014; 16:267-276. [PMID: 26190928 PMCID: PMC4496868 DOI: 10.1007/s10269-014-2391-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2013] [Accepted: 04/07/2014] [Indexed: 01/02/2023]
Abstract
BACKGROUND In 2006, bevacizumab, a targeted therapy agent was combined with FOLFIRI for the firstline treatment of patients with unresectable metastatic colorectal cancer. METHODS/RESULTS A study on a homogenous series of 111 patients from the Brittany and Pays de la Loire areas who received bevacizumab-FOLFIRI as first-line treatment in 2006 showed the following results: 51 responses, 29 stabilisations, 21 progressions and 10 cases of toxicity prior to assessment. Median overall survival (OS) was 25.1 months and median progression-free survival was 10.2 months. Surgery secondary to treatment tripled median OS which reached 59.2 months in resected patients versus 18.8 months in unresected patients. Comparison of patients aged more or less than 70 years showed no differences in terms of benefits or risks. CONCLUSION Bevacizumab-FOLFIRI could be administered as part of a routine care protocol to elderly patients previously evaluated by a geriatric assessment and validated by a multidisciplinary staff.
Collapse
Affiliation(s)
- J. P. Metges
- />CHU Brest Morvan, Brest, France
- />Observatoire dédié au Cancer de l’OMEDIT
Bretagne et de l’OMEDIT Pays de la Loire, Rennes, France
| | | | - R. Faroux
- />CH La Roche-Sur-Yon, La Roche-sur-Yon, France
| | - F. Riaud
- />CH La Roche-Sur-Yon, La Roche-sur-Yon, France
| | - E. Gamelin
- />ICO Paul Papin, Angers, France
- />Fondateur de l’Observatoire dédié au
cancer, Bretagne Pays de la Loire (ex-OMIT B PL), Rennes, France
| | | | | | | | - J. Y. Douillard
- />ICO René Gauducheau, Nantes, France
- />Observatoire dédié au Cancer de l’OMEDIT
Bretagne et de l’OMEDIT Pays de la Loire, Rennes, France
| | | | | | | | | | - O. Dupuis
- />Centre Jean Bernard/Clinique Victor-Hugo, Le Mans, France
| | - C. Grollier
- />Centre Jean Bernard/Clinique Victor-Hugo, Le Mans, France
| | | | | | | | | | | | - J. F. Ramée
- />Centre Catherine-de-Sienne, Nantes, France
| | - L. Guivarch
- />Centre Catherine-de-Sienne, Nantes, France
| | - P. L. Etienne
- />Clinique Armoricaine de Radiologie, Saint-Brieuc, France
- />Polyclinique Trégor-Lannion, Lannion, France
| | - S. Roussel
- />Clinique Armoricaine de Radiologie, Saint-Brieuc, France
| | | | | | | | - V. Klein
- />Hôpital Privé Océane/Centre Saint Yves
Vannes, Vannes, France
| | - R. Bessard
- />Hôpital Privé Océane/Centre Saint Yves
Vannes, Vannes, France
- />Observatoire dédié au Cancer de l’OMEDIT
Bretagne et de l’OMEDIT Pays de la Loire, Rennes, France
| | | | | | | | - S. Gouva
- />CH Landerneau, Landerneau, France
| | | | | | | | | | | | - E. Jobard
- />CH Saint-Brieuc, Saint-Brieuc, France
| | - E. Peguet
- />CH Saint-Brieuc, Saint-Brieuc, France
| | | | | | | | | | | | | | - P. Deguiral
- />Clinique Mutualiste de l’Estuaire, Saint-Nazaire, France
| | - L. Derenne
- />Clinique Mutualiste de l’Estuaire, Saint-Nazaire, France
| | - D. Martin
- />Polyclinique du Maine/Centre Mallet Proux Laval, Laval, France
| | | | - C. Bodin
- />Polyclinique du Maine/Centre Mallet Proux Laval, Laval, France
| | - V. Rossi
- />CH Haut Anjou Château Gontier, Château Gontier,
France
| | - S. Barré
- />CH Haut Anjou Château Gontier, Château Gontier,
France
| | | | | | - A. M. Vidal
- />CH Le Mans, Le Mans, France
- />Observatoire dédié au Cancer de l’OMEDIT
Bretagne et de l’OMEDIT Pays de la Loire, Rennes, France
| | - I. Cumin
- />CH Sud Lorient Hennebont, Hennebont, France
| | - J. Egreteau
- />CH Sud Lorient Hennebont, Hennebont, France
| | - A. Brouard
- />CH Sud Lorient Hennebont, Hennebont, France
| | | | | | | | | | | | | | - E. Crespeau
- />Polyclinique du Parc Cholet, Cholet, France
| | | | - H. Bourgeois
- />Observatoire dédié au Cancer de l’OMEDIT
Bretagne et de l’OMEDIT Pays de la Loire, Rennes, France
| | - C. Riche
- />Observatoire dédié au Cancer de l’OMEDIT
Bretagne et de l’OMEDIT Pays de la Loire, Rennes, France
| | - D. Déniel Lagadec
- />Observatoire dédié au Cancer de l’OMEDIT
Bretagne et de l’OMEDIT Pays de la Loire, Rennes, France
| | - F. Marhuenda
- />Observatoire dédié au Cancer de l’OMEDIT
Bretagne et de l’OMEDIT Pays de la Loire, Rennes, France
| | - F. Grudé
- />Observatoire dédié au Cancer de l’OMEDIT
Bretagne et de l’OMEDIT Pays de la Loire, Rennes, France
| |
Collapse
|
28
|
Goineau A, Mahé MA, Paineau J, Campion L, Rio E. [Sexual functions after treatment for rectal cancer: impact of doses in autonomic pelvic nerves]. Cancer Radiother 2014; 18:757-62. [PMID: 25457790 DOI: 10.1016/j.canrad.2014.10.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2014] [Revised: 09/08/2014] [Accepted: 10/03/2014] [Indexed: 12/15/2022]
Abstract
PURPOSE Prospective evaluation of sexual function after treatment of rectal cancer and identification of predictive factors. PATIENTS AND METHODS Thirty-three patients were treated with curative intent by chemoradiation and surgery for localized rectal adenocarcinoma. Sexual toxicity was assessed four times (before treatment and at 2, 6 and 12 months) using validated questionnaires: QLQ C30 and EORTC CR38 for all, simplified IIEF for men and FSFI for women. A correlation was sought between the toxicity and clinical and dosimetric parameters by Fisher and Mann-Whitney tests. RESULTS In men, erections and sexual satisfaction decreased significantly from the acute phase and then stabilized (respective scores of 84.5 and 86/100 in the initial phase, 66 and 70.4 at the end of radiotherapy, 70 and 70 at 6 months and 68.5 and 70 at 12 months). For women, the changes were not significant. This study confirms some risk factors for sexual toxicity already mentioned (original function, age, tumor volume) and highlights new (dose to the seminal vesicles and above all, doses to pelvic autonomic plexus). CONCLUSION Sexual effects of combined treatment of rectal cancer have only recently been described but remain undervalued and poorly understood. The impact of the autonomic pelvic plexus doses is a completely new data that could be extended in the development of intensity-modulated radiotherapy.
Collapse
Affiliation(s)
- A Goineau
- Département de radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain cedex, France.
| | - M-A Mahé
- Département de radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain cedex, France
| | - J Paineau
- Département de chirurgie digestive, institut de cancérologie de l'Ouest René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain cedex, France
| | - L Campion
- Département de biostatistiques, institut de cancérologie de l'Ouest René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain cedex, France
| | - E Rio
- Département de radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain cedex, France
| |
Collapse
|
29
|
Rousseau T, Lacoste J, Potiron E, Le Coguic G, Nevoux P, Aillet G, Campion L, Rousseau C. Intérêt de la technique isotopique du ganglion sentinelle associée aux outils préopératoires de prédiction du risque d’envahissement ganglionnaire dans le cancer de la prostate : à propos de 200 patients. Prog Urol 2014; 24:785-6. [DOI: 10.1016/j.purol.2014.08.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
30
|
Goineau A, Bardet E, Malard O, Lisbona A, Campion L. Curiethérapie postopératoire des carcinomes épidermoïdes résecables de la langue. Cancer Radiother 2014. [DOI: 10.1016/j.canrad.2014.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
31
|
Doré M, Cellier P, Campion L, Cutuli B, Leblanc-Onfroy M. Étude rétrospective de l’irradiation adjuvante hypofractionnée du cancer du sein infiltrant chez la femme âgée. Cancer Radiother 2014. [DOI: 10.1016/j.canrad.2014.07.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
32
|
Mahe M, Thomas L, De La Rochefordière A, Noel G, Le Blanc-Onfroy M, Campion L, Delpon G, Jouglar E. Early Clinical Outcomes in Cervical Cancer Treated With Extended Field Helical Tomotherapy to Para-Aortic Lymph Nodes. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
33
|
Adalsteinsson VA, Tahirova N, Tallapragada N, Yao X, Campion L, Angelini A, Douce TB, Huang C, Bowman B, Williamson CA, Kwon DS, Wittrup KD, Love JC. Single cells from human primary colorectal tumors exhibit polyfunctional heterogeneity in secretions of ELR+ CXC chemokines. Integr Biol (Camb) 2014; 5:1272-81. [PMID: 23995780 DOI: 10.1039/c3ib40059j] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Cancer is an inflammatory disease of tissue that is largely influenced by the interactions between multiple cell types, secreted factors, and signal transduction pathways. While single-cell sequencing continues to refine our understanding of the clonotypic heterogeneity within tumors, the complex interplay between genetic variations and non-genetic factors ultimately affects therapeutic outcome. Much has been learned through bulk studies of secreted factors in the tumor microenvironment, but the secretory behavior of single cells has been largely uncharacterized. Here we directly profiled the secretions of ELR+ CXC chemokines from thousands of single colorectal tumor and stromal cells, using an array of subnanoliter wells and a technique called microengraving to characterize both the rates of secretion of several factors at once and the numbers of cells secreting each chemokine. The ELR+ CXC chemokines are highly redundant, pro-angiogenic cytokines that signal via the CXCR1 and CXCR2 receptors, influencing tumor growth and progression. We find that human primary colorectal tumor and stromal cells exhibit polyfunctional heterogeneity in the combinations and magnitudes of secretions for these chemokines. In cell lines, we observe similar variance: phenotypes observed in bulk can be largely absent among the majority of single cells, and discordances exist between secretory states measured and gene expression for these chemokines among single cells. Together, these measures suggest secretory states among tumor cells are complex and can evolve dynamically. Most importantly, this study reveals new insight into the intratumoral phenotypic heterogeneity of human primary tumors.
Collapse
Affiliation(s)
- Viktor A Adalsteinsson
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Montagna MT, Lovero G, Borghi E, Amato G, Andreoni S, Campion L, Lo Cascio G, Lombardi G, Luzzaro F, Manso E, Mussap M, Pecile P, Perin S, Tangorra E, Tronci M, Iatta R, Morace G. Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. Eur Rev Med Pharmacol Sci 2014; 18:661-674. [PMID: 24668706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND Candida bloodstream infections (BSI) represent an important problem in Intensive Care Units (ICUs). The epidemiology of candidemia is changing with an increase in the proportion of Candida (C.) non-albicans. OBJECTIVES An Italian 2-year observational survey on ICU was conducted to evaluate the species distribution and possible differences between BSI caused by C. albicans and C. non-albicans. For comparative purposes, we performed a European literature-based review to evaluate distribution and frequency of Candida spp. causing ICU candidemia, during the period 2000-2013. MATERIALS AND METHODS This laboratory-based survey involved 15 microbiology centers (GISIA-3 study). All candidemia episodes in adult patients were considered. Data were prospectively collected from 2007 to 2008. PubMed was searched for peer-reviewed articles. RESULTS In total, 462 candidemia episodes were collected. C. albicans accounted for 49.4% of the isolates, followed by C. parapsilosis (26.2%) and C. glabrata (10.4%). Mortality was higher in patients with C. non-albicans than C. albicans (47.3% vs. 32.4 %, p > 0.05). Among risk factors, parenteral nutrition was more common (p = 0.02) in non-albicans candidemia, while surgery was more frequent (p = 0.02) in C. albicans candidemia. Twenty-four relevant articles were identified. C. albicans was the predominant species in almost all studies (range 37.9% -76.3%). C. glabrata was commonly isolated in the German-speaking countries, France, UK and North Europe; C. parapsilosis in Turkey, Greece and Spain. CONCLUSIONS Although C. non-albicans BSI is increasing, our study shows that C. albicans is still the predominant species in ICU candidemia. There are differences in the epidemiology of Candida BSI among European countries, with a prevalence of C. glabrata and C. parapsilosis in Northern and Southern countries, respectively.
Collapse
Affiliation(s)
- M T Montagna
- Department of Biomedical Science and Human Oncology, Hygiene Section, University of Bari Aldo Moro, Bari, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Jouglar E, Delpon G, Campion L, Mahé A, Supiot S. PD-0238: Pancreas-sparing radiotherapy: A feasibility study in paediatric abdominal irradiation. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30343-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
36
|
Helou J, Clément-Colmou K, Sylvestre A, Campion L, Amessis M, Zefkili S, Raphael J, Bonnette P, Le Pimpec Barthes F, Périgaud C, Mahé MA, Giraud P. [Helical tomotherapy in the treatment of malignant pleural mesothelioma: The impact of low doses on pulmonary and oesophageal toxicity]. Cancer Radiother 2013; 17:755-62. [PMID: 24269017 DOI: 10.1016/j.canrad.2013.06.045] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2013] [Revised: 05/17/2013] [Accepted: 06/24/2013] [Indexed: 10/26/2022]
Abstract
PURPOSE To evaluate the adjuvant treatment of malignant pleural mesothelioma by helical tomotherapy and the impact of low doses on esophageal and pulmonary toxicity. PATIENTS AND METHODS Between June 2007 and May 2011, 29 patients diagnosed with malignant pleural mesothelioma received adjuvant radiotherapy by helical tomotherapy. The median age was 63 years (34-72). Histologically, 83 % of patients had epithelioid malignant pleural mesothelioma. Clinically, 45 % of patients were T3 and 55 % N0. Eighty six percent of the patients were treated by extrapleural pneumonectomy and 35 % received neoadjuvant chemotherapy with platinum and pemetrexed. The median dose in the pneumonectomy cavity was 50Gy at 2Gy/fraction. RESULTS The mean follow-up was 2.3 years after diagnosis. Overall survival at 1 and 2 years was 65 and 36 % respectively. The median survival from diagnosis was 18 months. Median lung volumes receiving 2, 5, 10, 13, 15 and 20Gy (V2, V5, V10, V13, V15 and V20) were 100, 98, 52, 36, 19 and 5 %. The median of the mean remaining lung dose was 11Gy. Two patients died of pulmonary complications, three patients had grade 3 lung toxicity, while esophageal grade 3-4 toxicity was observed in three other patients. No significant impact of clinical characteristics and dosimetric parameters were found on pulmonary toxicity, however a V10≥50 %, a V15≥15 % and mean lung dose of 10Gy or more had a tendency to be predictive of pulmonary toxicity (P<0.1). Moreover, in our analysis, the mean lung dose seems to have a significant impact on esophageal toxicity (P=0.03) as well as low doses to the controlateral lung: V5, V10 and V13 (P<0.05). CONCLUSION Helical tomotherapy is a promising technique in the multimodality treatment of malignant pleural mesothelioma. Low doses received by the contralateral lung appear to be the limiting factor. A dosimetric comparison with volumetric modulated arctherapy techniques would be interesting in this setting.
Collapse
Affiliation(s)
- J Helou
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Campion L, Deangelis N, Ferrante C, Verona R, Seetharam S, Manthey C, Snyder L. Abstract B269: Effects of blocking aberrantly expressed CSF-1R in Hodgkin lymphoma. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-b269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The human genome contains a large number of repetitive elements that have been suspected to play a role in human diseases. Recent literature has shown that aberrant activation of one of these repetitive elements, a long terminal repeat (LTR), leads to lineage inappropriate expression of the CSF-1 receptor (CSF-1R) transcript in Hodgkin's lymphoma (HL) clinical samples and cell lines. CSF1-R, also known as Feline McDonough Sarcoma (FMS), is the receptor for CSF-1 and IL-34, and under normal circumstances it plays an important role in monocyte survival, proliferation, and differentiation as well as osteoclast generation. Aberrant expression of CSF-1R has been shown previously to support proliferation and survival in HL cells. To confirm the role of CSF-1R in HL, we determined that 17 of 17 HL clinical samples and 7 of 7 HL cell lines were positive for the aberrant CSF-1R transcript by TaqMan and traditional PCR, while non-HL cell lines were negative for the aberrant CSF-1R transcript. The HL lines were further characterized for surface expression of CSF-1R by flow cytometry and CSF-1 secretion by ELISA. L-1236 cells expressed the highest levels of CSF-1R and CSF-1. Treatment of the HL cell lines with CSF-1R-Fc, resulted in reduced viability in four of the five lines, consistent with the hypothesis that HL cell lines are sensitive to CSF-1 as a growth factor. Additionally, it was found that treating the L-1236 HL cell line with the CSF-1R small molecule inhibitor JNJ-40646527 had a significant effect on viability of the HL cell line L-1236, with an IC50 of 264 nM at 72 hrs. JNJ-40646527 did not have a significant effect on the viability of several other HL cell lines. These results indicate that aberrant LTR driven CSF-1R expression may play a role in the pathogenesis of Hodgkin's lymphoma (HL) and could be a potential target for Hodgkin's lymphoma therapy.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B269.
Citation Format: Liam Campion, Nikki Deangelis, Catherine Ferrante, Raluca Verona, Shobha Seetharam, Carl Manthey, Linda Snyder. Effects of blocking aberrantly expressed CSF-1R in Hodgkin lymphoma. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B269.
Collapse
|
38
|
Le Brun JF, Dravet F, Campion L, Classe JM. [Diagnostic laparoscopy in gynecological cancer, prophylactic oophorectomy: feasibility study on 22 cases]. ACTA ACUST UNITED AC 2013; 43:229-34. [PMID: 24095301 DOI: 10.1016/j.jgyn.2013.08.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2013] [Revised: 07/09/2013] [Accepted: 08/13/2013] [Indexed: 11/19/2022]
Abstract
OBJECTIVES The purpose of our study was to assess the feasibility of outpatient laparoscopy in a cohort of 22 patients admitted for bilateral oophorectomy (n=11) and preoperative diagnostic laparoscopy (n=11). PATIENTS AND METHODS Between December 2012 and May 2013, we included 22 patients in our study. All selected patients received a questionnaire the day before surgery. The questionnaire consisted of chapters on intraoperatively, and the postoperative assessments of patients regarding a possible return home on the evening of surgery. The ability to output was measured with the score of Chung at the evening of surgery and in the morning before leaving. RESULTS The mean age of patients was 60 years. The average length of stay was 1.2 days. Postoperative pain tends to be higher in the morning in the bilateral oophorectomy group (P=0.06), nausea and vomiting are the same in both groups. In the bilateral oophorectomy group, six patients were able to go out and five wished it; in the diagnostic laparoscopy group nine patients were able to go out and two wished it, this difference was significant (P=0.041). DISCUSSION The outpatient hospital is the norm for many surgeries. In our study, 47% of patients able to go out wishing that output. This difference is important when comparing the two groups. There are more patients wishing an output in the oophorectomy group. This reduction in length of stay must be compensated by a medical and paramedical supervision at home. CONCLUSION A large number of surgical procedure are performed on an outpatient basis. Patients who underwent diagnostic laparoscopy are more fragile, they should receive active postoperative support to enable an outpatient hospital.
Collapse
Affiliation(s)
- J F Le Brun
- Institut de cancérologie de l'Ouest, boulevard J.-Monod, 44800 Saint-Herblain, France.
| | - F Dravet
- Institut de cancérologie de l'Ouest, boulevard J.-Monod, 44800 Saint-Herblain, France
| | - L Campion
- Institut de cancérologie de l'Ouest, boulevard J.-Monod, 44800 Saint-Herblain, France
| | - J M Classe
- Institut de cancérologie de l'Ouest, boulevard J.-Monod, 44800 Saint-Herblain, France
| |
Collapse
|
39
|
Michaud S, Kuntz A, Dupas D, Campion L, Bouchot O, Pfister C, Rigaud J. [Multicentric evaluation of a self-screening questionnaire for occupational bladder cancer]. Prog Urol 2013; 23:977-85. [PMID: 24090782 DOI: 10.1016/j.purol.2013.04.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2012] [Revised: 03/14/2013] [Accepted: 04/08/2013] [Indexed: 10/26/2022]
Abstract
OBJECTIVE Evaluate a self-screening questionnaire for bladder cancer of occupational origin and analyse an influence of exposure to a carcinogen bladder tumor on prognosis. PATIENTS AND METHODS Five hundred and thirty-one patients followed, between 2005 and 2010, for bladder cancer in two university centers have received a self-screening questionnaire derived from questionnaire KVP 08. Patients who responded positively to at least one of the items were considered to have a self-screening questionnaire "positive". Patients were finally invited to take an appointment for consultation in occupational pathology. RESULTS The response rate to self-screening questionnaire was 39.9% (212/531). It was "positive" in 82 cases (38.7%). Among the 82 patients with a self-screening questionnaire "positive", 46 patients consulted in occupational pathology (56%). Occupational exposure to a bladder carcinogen was documented in 91.3% of cases. Among the 22 patients who consulted in occupational pathology with a self-screening questionnaire "negative", an occupational exposure to a bladder carcinogen was documented in 13.6% of cases. The sensibility of the self-screening questionnaire was 91.3%, the specificity 86.4% and the accuracy 89.7%. The relative risk to have an occupational exposure if the self-screening questionnaire was "positive" was 6.69. The analysis of groups "positive" versus "negative" does not reveal any statistically significant difference in terms of tumor aggressiveness and disease-free survival. CONCLUSION The self-screening questionnaire was considered relevant with good reliability for detection of occupational exposure to a bladder carcinogen.
Collapse
Affiliation(s)
- S Michaud
- Clinique urologique, CHU Hôtel-Dieu, 1, place Alexis-Ricordeau, 44000 Nantes, France
| | | | | | | | | | | | | |
Collapse
|
40
|
Le Brun JF, Dejode M, Campion L, Jaffré I, Bordes V, Classe JM, Oger AS, Dravet F. Qualité de vie après lipomodelage : étude rétrospective à propos de 42 patientes. ANN CHIR PLAST ESTH 2013; 58:222-7. [DOI: 10.1016/j.anplas.2013.01.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2012] [Accepted: 01/13/2013] [Indexed: 11/30/2022]
|
41
|
Dejode M, Sagan C, Campion L, Houvenaeghel G, Giard S, Rodier J, Ferron G, Jaffre I, Levêque J, Bendavid C, Dravet F, Marchal F, Bordes V, Faure C, Tunon de Lara C, Classe J. Pure tubular carcinoma of the breast and sentinel lymph node biopsy: A retrospective multi-institutional study of 234 cases. Eur J Surg Oncol 2013; 39:248-54. [DOI: 10.1016/j.ejso.2012.12.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2012] [Revised: 10/28/2012] [Accepted: 12/07/2012] [Indexed: 10/27/2022] Open
|
42
|
Goineau A, Marchand V, Bourdin S, Rio E, Campion L, Lisbona A, Mahé M, Supiot S. Évaluation de la qualité de vie 54 mois après RCMI pour cancer de prostate localisé. Cancer Radiother 2012. [DOI: 10.1016/j.canrad.2012.07.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Helou J, Clément-Colmou K, Campion L, Amessis M, Perigaud C, Bonnette P, Zefkili S, Mahé MA, Giraud P. Tomothérapie hélicoïdale dans le traitement du mésothéliome pleural malin : impact des faibles doses sur la toxicité pulmonaire et œsophagienne. Cancer Radiother 2012. [DOI: 10.1016/j.canrad.2012.07.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
44
|
Goineau A, Marchand V, Bourdin S, Rio E, Campion L, Lisbona A, Mahe M, Supiot S. EP-1129 QUALITY OF LIFE 54 MONTHS AFTER HIGH-DOSE INTENSITY-MODULATED RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71462-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
45
|
Rousseau T, Lacoste J, Pallardy A, Campion L, Bridji B, Mouaden A, Testard A, Aillet G, Le Coguic G, Potiron E, Curtet C, Kraeber-Bodéré F, Rousseau C. Détection laparoscopique des ganglions sentinelles dans le cancer localisé de la prostate : résultats obtenus chez 70 premiers patients. Prog Urol 2012; 22:30-7. [DOI: 10.1016/j.purol.2011.05.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2011] [Revised: 05/26/2011] [Accepted: 05/29/2011] [Indexed: 11/25/2022]
|
46
|
Nguyen F, Abadie J, Loussouarn D, Ibisch C, Rieder N, Campion L, Belousov A, Bemelmans I, Hanzenne C, Campone M. PD08-10: High Frequency of Triple Negative Mammary Carcinomas in the Dog as Model of Human Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-pd08-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background Information: Relevant animal models of human breast cancer are currently lacking, especially regarding the triple-negative breast cancer (TNBC) subtype, for which efficient therapies are needed. Recent studies indicate that spontaneous canine mammary carcinomas (CMCs) (which are common in France due to absence of early neutering) resemble human breast cancers, by pathology, tumor genetics, and biological behavior. However, the current molecular classification of human breast cancer has not been evaluated in canine samples yet.
Objective: To establish the prognostic value of the human immunophenotypic classification in dogs To evaluate CMCs as a model of human breast cancer including TNBC.
Methods: 350 CMCs treated by surgery alone were obtained from the Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering (France) from 2005 to 2008. Recorded clinical data included breed, neutering, age at diagnosis, presence of metastases, cause and time to death. Histological records included the subtype of carcinoma, Elston & Ellis grade, presence of emboli and lymph node metastasis. By immunohistochemistry (IHC) using ER, PR, Her2 (Herceptest and Pathway® Her2), CK5/6, EGF-R and KI67, CMCs were classified into the subtypes of human breast cancer according to Nielsen et al. IHC analyses were independently reviewed by four pathologists.
Results: The preliminary data in this abstract are based on 200 cases. The mean age at diagnosis was 10.8±2.1 years. 72,7% of dogs were intact female (27,3% of late neutering). 41% of dogs died due to cancer progression (metastasis rate of 30%). The most common histologic subtype was simple tubulopapillary CMC (53%), then solid CMC (32%). The most common grades were grade II (49%) and III (43%). 53% of the tumours showed lymphatic emboli. 4 immunophenotypes were defined: luminal A (11.9%), luminal B (5.1%), basal-like (59.3%) and non basal-like (23.7%) triple negative CMCs. 8.8% of the CMCs were scored Her2 2+ but none were considered Her2-overexpressing as defined by a 3+ score, despite appropriate staining with the two well established methods. Predictive factors for specific survival were: dog weight (p=0.01), histologic subtype (p=0.001), presence of emboli (p<0.0001) or lymph node metastasis (p=0.02), Ki67 index (p=0.03). Triple-negative carcinomas showed a significantly shorter specific survival (median=224 days) when compared to luminal A CMCs (median=641 days) (MannWhitney, p=0.016).
Conclusion: The molecular classification of human breast cancer identifies 4 subtypes of invasive CMCs with different prognoses. In dogs, a low rate of luminal tumors are observed, and no Her2-overexpressing tumors are found (defined by a score of 3+ by Her2 immunohistochemistry). 83% of CMCs were of the triple-negative subtype, associated with a shorter survival, as reported in human breast cancer. Infiltrative mammary cancer in dogs could be an interesting model for preclinical investigations. Final data based on 350 animals will be presented at the meeting.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr PD08-10.
Collapse
Affiliation(s)
- F Nguyen
- 1Ecole Nationale Veterinaire-ONIRIS, Site Chantrerie- BP4076, Nantes, France; Roche Diagnostics GmbH; Nonenwald 2, Penzberg, Germany; CHU de Nantes, Site Nord-Laennec, Nantes, France; Institut de Cancerologie de l'Ouest, Site Gauducheau, Bvd J Monod, Saint-Herblain (Nantes), France
| | - J Abadie
- 1Ecole Nationale Veterinaire-ONIRIS, Site Chantrerie- BP4076, Nantes, France; Roche Diagnostics GmbH; Nonenwald 2, Penzberg, Germany; CHU de Nantes, Site Nord-Laennec, Nantes, France; Institut de Cancerologie de l'Ouest, Site Gauducheau, Bvd J Monod, Saint-Herblain (Nantes), France
| | - D Loussouarn
- 1Ecole Nationale Veterinaire-ONIRIS, Site Chantrerie- BP4076, Nantes, France; Roche Diagnostics GmbH; Nonenwald 2, Penzberg, Germany; CHU de Nantes, Site Nord-Laennec, Nantes, France; Institut de Cancerologie de l'Ouest, Site Gauducheau, Bvd J Monod, Saint-Herblain (Nantes), France
| | - C Ibisch
- 1Ecole Nationale Veterinaire-ONIRIS, Site Chantrerie- BP4076, Nantes, France; Roche Diagnostics GmbH; Nonenwald 2, Penzberg, Germany; CHU de Nantes, Site Nord-Laennec, Nantes, France; Institut de Cancerologie de l'Ouest, Site Gauducheau, Bvd J Monod, Saint-Herblain (Nantes), France
| | - N Rieder
- 1Ecole Nationale Veterinaire-ONIRIS, Site Chantrerie- BP4076, Nantes, France; Roche Diagnostics GmbH; Nonenwald 2, Penzberg, Germany; CHU de Nantes, Site Nord-Laennec, Nantes, France; Institut de Cancerologie de l'Ouest, Site Gauducheau, Bvd J Monod, Saint-Herblain (Nantes), France
| | - L Campion
- 1Ecole Nationale Veterinaire-ONIRIS, Site Chantrerie- BP4076, Nantes, France; Roche Diagnostics GmbH; Nonenwald 2, Penzberg, Germany; CHU de Nantes, Site Nord-Laennec, Nantes, France; Institut de Cancerologie de l'Ouest, Site Gauducheau, Bvd J Monod, Saint-Herblain (Nantes), France
| | - A Belousov
- 1Ecole Nationale Veterinaire-ONIRIS, Site Chantrerie- BP4076, Nantes, France; Roche Diagnostics GmbH; Nonenwald 2, Penzberg, Germany; CHU de Nantes, Site Nord-Laennec, Nantes, France; Institut de Cancerologie de l'Ouest, Site Gauducheau, Bvd J Monod, Saint-Herblain (Nantes), France
| | - I Bemelmans
- 1Ecole Nationale Veterinaire-ONIRIS, Site Chantrerie- BP4076, Nantes, France; Roche Diagnostics GmbH; Nonenwald 2, Penzberg, Germany; CHU de Nantes, Site Nord-Laennec, Nantes, France; Institut de Cancerologie de l'Ouest, Site Gauducheau, Bvd J Monod, Saint-Herblain (Nantes), France
| | - C Hanzenne
- 1Ecole Nationale Veterinaire-ONIRIS, Site Chantrerie- BP4076, Nantes, France; Roche Diagnostics GmbH; Nonenwald 2, Penzberg, Germany; CHU de Nantes, Site Nord-Laennec, Nantes, France; Institut de Cancerologie de l'Ouest, Site Gauducheau, Bvd J Monod, Saint-Herblain (Nantes), France
| | - M Campone
- 1Ecole Nationale Veterinaire-ONIRIS, Site Chantrerie- BP4076, Nantes, France; Roche Diagnostics GmbH; Nonenwald 2, Penzberg, Germany; CHU de Nantes, Site Nord-Laennec, Nantes, France; Institut de Cancerologie de l'Ouest, Site Gauducheau, Bvd J Monod, Saint-Herblain (Nantes), France
| |
Collapse
|
47
|
Classe J, Jaffre I, Frenel J, Bordes V, Dejode M, Dravet F, Ferron G, Marchal F, Berton Rigaud D, Loussouarn D, Campion L. Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases. Eur J Surg Oncol 2011; 37:971-7. [DOI: 10.1016/j.ejso.2011.08.138] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2011] [Revised: 08/23/2011] [Accepted: 08/28/2011] [Indexed: 01/08/2023] Open
|
48
|
Bompas E, Campion L, Italiano A, Cesne AL, Giaj Levra M, Chevreau C, Piperno-Neumann S, Isambert N, Thyss A, Rios M, Kurtz J, Delcambre C, Bay J, Duffaud F, Trassard M, Soulie P, Blay J. Outcome of 157 adult rhabdomyosarcoma (RMS) patients: A retrospective study from the French Group Sarcoma (GSF-GETO). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10070] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Shi FF, Campion L, Kaiser E, Ferrante C, Wiley D, McCabe F, Doshi P, Snyder L. Abstract 555: CCL2 promotes pancreatic tumor growth and is upregulated in tumor-stroma models. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CCL2 (C-C chemokine ligand 2; also known as MCP-1) is a pleiotropic chemokine overexpressed by many types of tumors. CCL2 is believed to promote tumor growth by increasing macrophage infiltration, angiogenesis, tumor proliferation/survival, and metastasis. The purpose of these studies was to assess potential mechanisms of action associated with the efficacy of neutralizing CCL2 in human pancreatic xenograft models.
Cell lines included BxPC-3, PANC-1 and AsPC-1 human pancreatic carcinoma, all of which are p53mut/krasmut, but each differentially expresses CCL2 and its receptor, CCR2. The three tumor cell lines were implanted subcutaneously in immunocompromised mice. When tumors reached ∼50-100 mm3, a cocktail of neutralizing antibodies to human CCL2, mouse MCP-1 and mouse MCP-5 (termed CCL2 blockade) was administered i.p. at 10 mg/kg each, twice a week for the study duration, either alone or in combination with gemcitabine i.p. at 120 mg/kg q3dx4. CCL2 blockade alone significantly inhibited primary tumor growth for BxPC-3 (66-78% tumor growth inhibition (TGI); P<0.001) or prolonged survival for PANC-1 (by seven days; P<0.004). CCL2 in combination with gemcitabine significantly inhibited AsPC-1 tumor growth compared to either therapy alone (55% TGI; P<0.034). By IHC analysis, macrophage infiltration in AsPC-1 tumors was reduced significantly by CCL2 blockade (P=0.049).
In vitro studies were conducted to further understand the mechanism of action. Recombinant huCCL2 had no effect on pancreatic tumor cell proliferation in vitro, suggesting that the in vivo anti-tumor effect by CCL2 blockade may be through CCL2 neutralization within the host stroma. Co-culture studies to mimic the tumor-stroma interaction were conducted, using pancreatic tumor cells and normal human lung fibroblasts (NHLF). Secretion of CCL2, as well as IL-5, IL-6, IL-6R, IL-8 and GRO, was significantly enhanced 2-10-fold during co-culture of BxPC3 with NHLF (P<0.001), while only CCL2 was enhanced 2-fold during PANC-1/NHLF co-culture (P<0.001).
Furthermore, cell-cell contact was not required for cytokine induction for both BxPC-3 and PANC-1 with NHLF. Tumor cell conditioned medium (CM) stimulated NHLF to produce cytokines, not vice versa, suggesting that a factor(s) in tumor CM is responsible for cytokine induction. Neutralizing antibodies to either CCL2 or IL-6 did not abolish induction of other cytokines in the BxPC-3/NHLF model. The inducers of chemokines/cytokines as well as in vitro migration and in vivo gene profiling studies are underway to better understand the impact of CCL2 blockade on pancreatic tumor growth. These results demonstrate the significant effect of CCL2 blockade on pancreatic tumor growth in vivo, and suggest that the tumor cell/fibroblast interaction may be an important source of CCL2 at the tumor site.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 555.
Collapse
Affiliation(s)
- Frank F. Shi
- 1Ortho Biotech Oncology Discovery Research, Centocor Research & Development, Inc., Radnor, PA
| | - Liam Campion
- 1Ortho Biotech Oncology Discovery Research, Centocor Research & Development, Inc., Radnor, PA
| | - Elizabeth Kaiser
- 1Ortho Biotech Oncology Discovery Research, Centocor Research & Development, Inc., Radnor, PA
| | - Catherine Ferrante
- 1Ortho Biotech Oncology Discovery Research, Centocor Research & Development, Inc., Radnor, PA
| | - Diana Wiley
- 1Ortho Biotech Oncology Discovery Research, Centocor Research & Development, Inc., Radnor, PA
| | - Frank McCabe
- 1Ortho Biotech Oncology Discovery Research, Centocor Research & Development, Inc., Radnor, PA
| | - Parul Doshi
- 1Ortho Biotech Oncology Discovery Research, Centocor Research & Development, Inc., Radnor, PA
| | - Linda Snyder
- 1Ortho Biotech Oncology Discovery Research, Centocor Research & Development, Inc., Radnor, PA
| |
Collapse
|
50
|
Campion L, Shi F, Kaiser E, Johns L, Egenolf D, Ferrante C, McCabe F, Millar H, Rafferty P, Rudnick K, Bugelski P, Snyder L. Neutralizing CCL2 Inhibits Breast Tumor Growth Via Impact on the Tumor/Stroma Microenvironment. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-6095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CCL2, (CC-chemokine ligand 2 or monocyte chemoattractant protein-1 (MCP-1)), is overexpressed in many human tumors and is believed to exert pro-tumor effects by recruiting monocytes to the tumor, where these cells become tumor associated macrophages (TAMs). TAMs secrete growth factors that stimulate angiogenesis and tumor growth, as well as proteases to promote tumor invasion and metastasis. CCL2 expression levels in primary breast tumors have been correlated with macrophage infiltration and blood vessel density, which in turn is correlated with disease stage and prognosis. These correlations indicate that CCL2 is a key player in tumor macrophage infiltration and/or tumor growth/invasion, and suggest that neutralizing CCL2 could be an effective form of therapy for breast cancer patients.The objective of these studies was to investigate whether CCL2 blockade could inhibit tumor growth in mice bearing human breast tumors. The human breast tumor cell lines MDA-MB-231 (ER-, PR-, Her2-) and MDA-MB-361 (ER+, PR+, Her2+) were implanted orthotopically in immunocompromised mice, and in both models the primary tumors metastasized to lungs and brain. Neutralizing antibodies to human CCL2 (CNTO 888) and to the mouse orthologs, MCP-1 and MCP-5, were administered therapeutically, either as a cocktail (termed CCL2 blockade) or individually to study the relative roles of host vs tumor derived CCL2 in promoting tumor growth.In both tumor models, CCL2 blockade significantly inhibited the growth of established primary tumors in the mammary fat pad. In addition, CCL2 blockade inhibited metastasis to distant sites. As measured by Taqman, visual inspection and immunohistochemistry, mice with MDA-MB-361 tumors treated with CCL2 blockade showed significantly reduced metastasis to lungs and brain, while mice bearing MDA-MB-231 tumors showed significantly reduced metastasis to lungs.To define the relative roles of human tumor-derived CCL2 vs mouse host-derived MCP-1/MCP-5, in vivo monotherapy tumor studies were conducted using the individual neutralizing antibodies. These studies included the mammary fat pad model and a tail vein metastasis model. In both cases, only the treatment with the anti-mouse MCP-1 antibody significantly inhibited primary tumor growth and distant metastasis, indistinguishable from the effect of CCL2 blockade treatment. In the tail vein metastasis model, the antibody treatment resulted in significantly fewer detectable lesions with these lesions showing a significant reduction in both tumor size and growth fraction, suggesting antibody treatment inhibits tumor seeding and growth. Mechanistic studies are in progress to further understand the basis of the anti-tumor effect mediated by the antibody treatment. These results demonstrate that host-derived MCP-1, produced from the tumor microenvironment, plays the critical role in tumor growth and metastasis in these models of human breast cancer.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6095.
Collapse
Affiliation(s)
| | - F. Shi
- 1Ortho Biotech, Centocor, PA,
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|